Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) ...
Objective Heart failure (HF) is common with high associated morbidity and mortality. UK National Institute for Health and ...
Given the success of the previous collection, The Complex Phenotype of Diabetic Cardiomyopathy: Clinical Indicators and Novel Treatment Targets, and new advances in the field, we are pleased to ...
Background Ebstein’s anomaly (EA) exhibits significant anatomical and clinical heterogeneity, warranting a systematic ...
The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...
Pharmaceutical Technology on MSN
Cytokinetics receives FDA approval for MYQORZO tablets for oHCM
Cytokinetics has announced that the US Food and Drug Administration (FDA) has approved MYQORZO (aficamten) tablets in 5mg, 10mg, 15mg, and 20mg doses for adults with symptomatic obstructive ...
Follow ZDNET: Add us as a preferred source on Google. Inside our homes, though, Amazon Alexa has become the most popular virtual assistant in the US and around the world, as a widely adopted virtual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback